• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

Introduction to 5-Bromo-2-Ethyl-3,4-Dihydropyrimidin-4-One (CAS No. 1528580-99-5)

5-Bromo-2-Ethyl-3,4-dihydropyrimidin-4-one (CAS No. 1528580-99-5) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of dihydropyrimidinones, which are known for their diverse biological activities and potential therapeutic applications. The presence of a bromine atom and an ethyl group in its structure imparts unique chemical and biological properties, making it a valuable candidate for various research and development initiatives.

The chemical structure of 5-bromo-2-ethyl-3,4-dihydropyrimidin-4-one is characterized by a six-membered ring with a keto group at the 4-position and a bromine substituent at the 5-position. The ethyl group at the 2-position further enhances its solubility and reactivity, making it suitable for a wide range of synthetic transformations. This compound can be synthesized through various methods, including Biginelli reactions and other multicomponent reactions, which are well-documented in the literature.

Recent studies have highlighted the potential of 5-bromo-2-ethyl-3,4-dihydropyrimidin-4-one in the development of novel drugs. One notable application is its use as an intermediate in the synthesis of antiviral agents. Research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent antiviral activity against a range of viruses, including influenza and hepatitis C. The bromine substituent plays a crucial role in enhancing the antiviral efficacy by modulating the interaction with viral enzymes.

In addition to its antiviral properties, 5-bromo-2-ethyl-3,4-dihydropyrimidin-4-one has also been explored for its potential as an anticancer agent. Studies conducted by researchers at the National Cancer Institute have demonstrated that certain derivatives of this compound can inhibit the growth of cancer cells by targeting specific signaling pathways. The ethyl group at the 2-position contributes to the selectivity and potency of these derivatives, making them promising candidates for further preclinical and clinical evaluation.

The pharmacokinetic properties of 5-bromo-2-ethyl-3,4-dihydropyrimidin-4-one have also been investigated to assess its suitability as a drug candidate. Research published in the European Journal of Pharmaceutical Sciences has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. Its high solubility and low toxicity make it an attractive candidate for oral administration, which is a desirable feature for many pharmaceutical applications.

The safety profile of 5-bromo-2-ethyl-3,4-dihydropyrimidin-4-one has been evaluated through various in vitro and in vivo studies. Toxicity assessments have indicated that this compound is generally well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models. These findings support its potential use in clinical settings and provide a strong foundation for further development.

In conclusion, 5-bromo-2-ethyl-3,4-dihydropyrimidin-4-one (CAS No. 1528580-99-5) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable biological properties make it an attractive candidate for the development of novel drugs targeting viral infections and cancer. Ongoing research continues to explore its full potential, paving the way for innovative therapeutic solutions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)